natgillin/translations-raw huggingface dataset:
The method according to claim 17 or 18, comprising crystallising by precipitation the base of Compound I from the solvent, and separating the solvent from the obtained crystalline base of Compound I. 
Postupak prema zahtjevu 17 ili obuhvaća kristalizaciju pomoću taloženja baze Spoja I iz otapala, i odvajanje otapala od dobivene kristalične baze Spoja I.
is selected from the group consisting of hydrogen, fluoro, hydroxy, and methoxy; 
do X4 su neovisno odabrani iz skupine koju čine C i N;
Remote meter according to anyone of claims 27 to 29, further adapted to perform the operation of transmitting periodically measured and stored consumption related data stored in L storage locations at the remote meter (RM) said number (L) of storage locations received from the concentrator (C). 
Daljinski brojač prema bilo kojem od patentnih zahtjeva 27 do 29, koji je nadalje prilagođen za provođenje operacija prijenosa periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju pohranjenih na L lokacijama za pohranu na daljinskom brojaču (RM) pri čemu je navedeni broj (L) lokacija za pohranu dobiven iz sabirnika (C).
The title compound was prepared from 1-benzyl-5-hydroxy-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonitrile (see Example 9.7) using a similar procedure described for the synthesis of Example 9.8. 
Naslovni spoj je pripremljen iz 1-benzil-5-hidroksi-1,4,5,6-tetrahidro-ciklopenta[c]pirazol-3-karbonitrila (vidi Primjer 9.7) na sličan način kako je to opisano za sintezu u Primjeru 9.8.
A device as claimed in claim 1, characterised in that each filtration station (15a, 15b, 15c) presents at least a first support (7a, 7b, 7c) and a second support (9a, 9b, 9c) for said filters (13a, b, c, 14a, b, c). 
Uređaj kao što je naveden u patentnom zahtjevu 1, naznačen time što svaka stanica za filtriranje (15a, 15b, 15c) ima najmanje prvi oslonac (7a, 7b, 7c) i drugi oslonac (9a, 9b, 9c) za navedene filtre (13a, b, c, 144, b, c).
In one specific embodiment of the invention the anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment binding to adrenomedullin or anti-ADM non-Ig scaffold binding to adrenomedullin is provided for use in therapy of an acute disease or acute condition of a patient wherein said antibody or fragment or scaffold binds to a region of preferably at least 4, or at least 5 amino acids within the sequence of aa 1-21 of mature human ADM: 
Protutijelo protiv adrenomedđulina (ADM) ili fragment protutijela protiv ADM koji se veže na adrenomedulin ili okosnica ne-Ig protiv ADM koja se veže na adrenomedulin, namijenjeni upotrebi u terapiji akutne bolesti ili akutnog stanja kod pacijenta u skladu bilo kojim od patentnih zahtjeva 1 do 5, naznačeni time što navedeno protutijelo ili fragment ili okosnica nisu Protein-1 koji se veže na ADM, komplementni čimbenik H.
The coating material as recited in claim 1, wherein the hydroxy-functional binder component comprises from 5 to 40 wt % of the inorganic pigment based on a total weight of the hydroxy-functional binder component. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da vezivna komponenta sadrži od 5 do 40 masenih % anorganskih punila (ili anorganskih pigmenata bazi ukupne mase vezivne komponente.
is selected from the group consisting of aryl and heteroaryl groups optionally substituted with one or more substituents selected from the group consisting of halogen, halo C1-7 alkyl, C1-7 alkoxy, and alkylamino, and is hydrogen, or a pharmaceutical acceptable addition salt thereof, or a dihydro-derivative or a tetrahydro-derivative thereof, or a stereochemical isomeric form thereof, or a N-oxide thereof, or a solvate thereof. 
- R; je izabran iz grupe koju čine aril i heteroaril grupe izborno supstituirane sa jednim ili više supstituenata koji su izabrani iz grupe koju čine halogen, halo C,.; alkil, C;.; alkoksi 1 alkilamino, i - Rx je vodik, ili njegova farmaceutski prihvatljiva adicijska sol, ili njegov dihidro-derivat ili njegov tetrahidro-derivat, ili njegov stereokemijski izomerni oblik, ili njegov N-oksid, ili njegov solvat.
Subject matter of this invention is novel substituted 2-thioxo-imidazolidine-4-ones and their spiro analogues expressed by the general formula 1, wherein 
1. < Spojevi koji su (R)-stereoizomeri Supsttuiranih 2-tiokso-imidazolidin-4-ona koji su prikazani općom formulom 1, 3
A lyophilized pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof, a hydrate of the compound, or a hydrate of a pharmaceutically acceptable salt of the compound according to claim 1, and a pharmaceutically acceptable carrier, diluent or excipient wherein the pH of said composition when diluted with aqueous diluent is less than 4.2 and greater than 2.0. 
. Liofilizirani farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipient pri čemu pH spomenutog pripravka kada je razrijeđen s vodenastim razrjeđivačem je manji od 4,2 i veći od 2,0.
Use according to claim 8, wherein the ionizing radiations are of about 2 KeV to 1500 KeV. 
Uporaba ili nanočestice HfO, 1li agregati nanočestica HfO, za uporabu prema zahtjevu 6, gdje su ionizirajuća zračenja od oko 2 KeV do 1500 Kev.
A process according to claim 17 or 18, wherein the layer of adhesive is applied to an upper surface of the peripheral flange by a roller, by spray coating, by a hot melt gun or by a printing technique. 
Postupak prema patentnim zahtjevima 15 ili 16, pri čemu se sloj ljepila nanosi na gornju površinu oboda valjkom, prskanjem, toplim pištoljem ili tehnikom štampanja.
The fibers according to any one of claims 1-8, wherein said nano-sized diamond has a specific gravity of 2.63-3.38 g/cm3. Bedding formed by the fibers recited in any one of claims 1-9. 
7. < Vlakna u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što navedeni dijamant nano-veličine ima gustoću od 2,63-3,38 g/cm'. 8.
The crystalline dihydrogenphosphate salt monohydrate was found to be stable under ambient condition. 
Kristalni monohidrat dihidrogenfosfatne soli je stabilan pod ambijentalnim uvjetima.
The foil lined tube consisted of a 0.35 mil (0.0089 mm) layer of aluminum foil inside a 4.25 mil (0.108 mm) layer of white spirally wound paper. 
Cijev obložena sa folijom sastojala se je od sloja aluminijske folije od 0.0089 mm unutar sloja od bijelog spiralnog omotanog papira od 0.108 mm.
The present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of a disease or disorder, wherein a serotonin reuptake inhibitor is beneficial. 
Ovaj izum se također odnosi na uporabu spoja formule I za pripravu lijeka za liječenje bolesti ili poremećaja kod kojeg je djelotvoran inhibitor ponovne pohrane serotonina.
Compact fluorescent lamp according to claim 4 characterized in that cooling apertures (9) are formed on the base (1) and/or on the hollow column (2) and/or on the cap (3). 
Kompaktna fluorescentna žarulja prema zahtjevu 4 ili 5, naznačena time što se otvori za hlađenje (9) nalaze na grlu (1) ifili šupljoj cijevi (2) i/ili poklopcu (3).
A pharmaceutical tablet especially in accordance with the preceding items having a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test. 
Farmaceutska lablela prema bilo kojem od prethodnih zahtjeva naznačena time da ima silu loma od najmanje 110 N, poželjno 120 N, poželjnije 130 N, te najpoželjnije 140 N, kada je podvrgnuta indentacijskom testu.
As used herein, the above terms have the following meaning: 
Kao što ih se upotrebljava u ovoj specifikaciji, gornji pojmovi imaju sljedeća značenje:
The method of claim 4, wherein the aminooxy compound is chosen from compounds of Formula III: wherein Y is the second reactive group, n is chosen from integers ranging from 1 to 10, and P is chosen from amino protecting groups. 
(b) osiguravanje aminooksi spoja koji sadrži aminooksi skupinu i drugu reaktivnu skupinu, pri čemu je aminooksi spoj odabran od spojeva s Formulom III: i
Asenapine maleate was isolated by filtration and washed with a 1:1 mixture of acetone and heptane (30 kg) cooled to 10°C. The material was thereafter dried. 
Asenapin maleat je izoliran filtracijom i ispran s 1:1 smjesom acetona i heptana (30 kg) ohlađenih na 10 *C. Materijal je nakon toga osušen.
In a further aspect the invention provides a compound of the above formula I according to the above as the free base or a pharmaceutical acceptable salt thereof for use as a medicament. 
U jednom daljnjem aspektu izum daje spoj gore navedene formule I u skladu s gore navedenim kao slobodna baza ili njezina farmaceutski prihvatljiva sol za korištenje kao lijek.
The electrolytic cell according to any of claims 1-9, characterized in that the liquidus temperature of the electrolyte (4) is 620-670°C. An electrolysis process using the electrolytic cell according to any of claims 1-10, comprising the steps of: adding specified amounts of NaF, AlF3, LiF, KF and Al2O3 to a melting furnace for mixing and melting to form a melt; or adding specified amounts of NaF, AlF3, LiF and KF to a melting furnace for mixing and melting, and then adding Al2O3 to obtain a melt; and 
(1) dodavanja navedenih količina NaF, AIF;, LiF, KF i AbO> u peć za topljenje radi miješanja i topljenja da se formira istopljena masa; ili dodavanja navedenih količina NaF, AIF;, LiF i KF u peć za topljenje radi miješanja i topljenja, i potom dodavanja Al2O; da se dobije istopljena masa; i (2) podizanja temperature istopljene mase pripremljene u koraku (1) do iznad 720-760"C, 1 potom, sipanja otopljenje mase u elektrolitičku stanicu 1 izvođenja elektrolize dok se temperature održava na 720-760%C.
In some of these embodiments, R2 is pyrimidine substituted with one or more —Cl, —F, —CH3, —CF3, —N(CH3)2, -D, or —CD3. 
Kemijski entitet prema zahtjevu 1 ili 2, gdje R? je pirimidin supstituiran sa jednim ili više članova nezavisno izabranim iz grupe koju čine -CI, -F, -CH., -CF3, -N(CH3),, -D, ili -CD:.
adjusting the pressure in the space between the provisions and the air-tight covering to a third value, higher than or equal to the first value, for pushing away the plastic material-filled channels created outside the air-tightly covered reinforcement package; 
- < namještanje pritiska u prostoru između pomoćnih sredstava i neprodušnog pokrova na treću vrijednost, višu od prve vrijednosti ili jednaku prvoj vrijednost, za odmicanje kanala ispunjenih s plastičnim materijalom nastalih izvan neprodušno pokrivenog tijela za ojačanje;
A method according to paragraph 1, characterised in that the pre-expanded polymer beads are preheated before leading them into the casting mould. 
Postupak prema zahtjevu 1, naznačen time što se pred-ekspandirane polimerne kuglice prethodno zagrijavaju prije nego se uvode u kalup za lijevanje.
Methane sulfinic acid sodium salt (20.1 g, 200 mmol) is added to a stirred solution of 3,4-difluorobenzaldehyde (22.5 g, 158 mmol) in dry DMSO (200 ml) at 75° C. After 2 hours the reaction is poured onto ice-water (200 ml). 
Natrijevu sol metansulfinske kiseline (20,1 g, 200 mmolova) doda se u miješanu otopinu 3,4-difluorbenzaldehida (22,5 g, 158 mmola) u suhom DMSO (200 ml) pri 75C. Nakon 2 sata reakcijsku smjesu se prelije na led-vodu (200 ml).
A combination according to any of the preceding claim for use in potentiating the analgesic effect of opioids or opiates and/or for decreasing the dependency induced thereby. 
Sastav prema bilo kojem od prethodnih zahtjeva za uporabu u potenciranju analgetičkog efekta opioida ili opijata iili za smanjenje njima uzrokovane ovisnosti.
The compound for use in a method of treatment as described in any one of claims 7 to 12, the method comprising administering to the patient a therapeutically effective amount of the compound in combination with at least one additional active agent selected from the group consisting of an inhibitor of protein kinase A (PKA), an inhibitor of cAMP signaling, a nonsteroidal anti-inflammatory drug, a prostaglandin synthesis inhibitor, a local anesthetic, an anticonvulsant, an antidepressant, an opioid receptor agonist, a neuroleptic, an agonist of GABAA receptor, an analgesic agent that acts by a mechanism different from a PKCe antagonist, a benzodiazepine, a barbiturate, a neurosteroid and a inhalation anesthetic, a anesthetic, an anticancer drug, a modulator of mGluR5 receptor, and a combination thereof. 
Spoj za uporabu u postupku liječenja prema bilo kojem od zahtjeva 7 do 12, naznačen time, da postupak obuhvaća davanje pacijentu terapeutski učinkovite količine spoja u kombinaciji s najmanje jednom dodatnom djelotvornom tvari odabranom iz skupine koju čine: inhibitor kinaze A proteina (PKA), inhibitor signalizacije za cAMP, nesteroidni protuupalni lijek, inhibitor sinteze prostaglandina, lokalni anestetik, antikonvulzijsko sredstvo, antidepresiv, agonist receptora opi oida, neuroleptik, agonist receptora GABAA, analgetsko sredstvo koje djeluje putem mehanizma različitog od antagonista za PKCe, benzodiazepin, barbiturat, neurosteroid i anestetik za inhaliranje, anestetik, lijek protiv raka, modulator receptora mGluR5, i njihova kombinacija.
moving the laser beam along the surface of the target, such that the plume moves in a radial direction in relation to the rotation axis; 
- < pomicanje lasera ili elektronske zrake duž ciljne površine, tako da se prašina pomiče radijalno u odnosu na rotacijsku os; naznačen time što
The aqueous formulation for use of claim 18 wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 18, naznačena time što navedeni farmaceutski pripravak dodatno sadrži pomoćne tvari, koje se bira iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
A polymorph, a use or a pharmaceutical compostion according to any one of claims 15 to 17 wherein the treatment is for depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke. 
Polimorf, upotreba ili farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 15 do 17, gdje liječenje je usmjereno na depresiju, anksioznost, Alzheimerovu bolest, slabljenje kognitivnih funkcija uzrokovano starenjem, ADHD, pretilost, blago slabljenje kognitivnih funkcija, shizofreniju, deficijentnost kognitivnih funkcija kod shizofrenije, te inzult.
The pharmaceutical composition according to claim 18, wherein the δ-amino-Y-hydroxy-w-aryl-alkanoic acid amide derivative is a compound of formula (I) wherein R1 is 3-methoxypropoxy; R2 is methoxy; and R3 and R4 are isopropyl; or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak u skladu sa zahtjevom 18, naznačen time, da derivat amida 5-amino-y-hidroksi-o-aril- alkanoične kiseline je spoj formule (I) gdje Ri je 3-metoksipropoksi; R» je metoksi; te Ra i Ra su izopropil; ili je njegova farmaceutski prihvatljiva sol.
by means of screening, filtration, or centrifugation. 
sijanjem kroz sito, filtracijom ili centrifugiranjem.
an electrical motor (4) with driving shaft (40), said electric motor (4) being adapted to be used in explosion risk areas; characterized in that the system also comprises: 
Elektromotor (4) s pogonskom osovinom (40), spomenuti elektromotor je prilagođen za korištenje u područjima s rizikom eksplozije; naznačen time da sustav također sadrži: a
Any of the above embodiments are also embodiments of formula ID with the proviso that R9 does not exist in compounds of general formula ID. 
Bilo koji od oblika koji su gore navedeni također predstavljaju oblike formule ID pod uvjetom da R* ne postoji u spojevima opće formule ID.
Process according to claim 1 in which, in proximity of the central axis of revolution of said toroidal flow pattern, the flow vectors change orientation showing downwardly orientation(s), hence reflecting significant downward movement of the melt in proximity of the said axis, notably in which, at the melter bottom, the flow vectors change orientation showing orientation(s) which are outward and then upwards again. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što, u blizini središnje osi vrtnje navedenog toroidnog uzorka tečenja, vektori tečenja koji mijenjaju smjer pokazuju prema dolje jedan ili više smjerova, odražavajući značajno gibanje taline prema dolje u blizini navedene osi, osobito gdje, na dnu talionika, vektori tečenja koji mijenjaju smjer pokazuju jedan ili više smjerova koji idu prema van, pa ponovno prema gore.
The process according to claim 1, characterized in that the at least one mineral material is selected from the group comprising natural calcium carbonate (GCC) such as marble, chalk, limestone; precipitated calcium carbonate (PCC) such as aragonitic PCC, vateritic PCC and/or calcitic PCC, especially prismatic, rhombohedral or scalenohedral PCC; surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; and mixtures thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time da je barem jedan mineralni materijal izabran iz skupine koja sadrži prirodni kalcij karbonat (GCC), poput mramora, krede, vapnenca; istaloženi kalcij karbonat (PCC) poput aragonitskog PCC; vateritskog PCC iili kalcitskog PCC; posebno prizmatični, rombohedralni ili skalenohedralni PCC; kalcij karbonat modificirane površine; dolomit; talk; bentonit; glina; magnezit; satensko bijelilo; sepiolit, huntit, diatomit; silikate; te njihove smjese.
The composition of any one of claims 1-3, wherein the polypeptide comprises an amino acid sequence that is at least 85%, at least 89%, at least 95%, or at least 99% identical to the amino acid sequence of SEQ ID NO: 1 or comprises the amino acid sequence of SEQ ID NO: 1. 
Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 1, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu koja je najmanje 85% identična aminokiselinskoj sekvenci SEQ ID NO: 1.
any hydrophobic residues in the up to three amino acids at the N or C terminus of the native sequence of the peptide, which are not comprised in a T cell epitope, are deleted; and/or vi) any two consecutive amino acids comprising the sequence Asp-Gly in the up to four amino acids at the N or C terminus of the native sequence of the peptide, which are not comprised in a T cell epitope, are deleted. 
V) svaki hidrofobni ostaci sve do tri aminokiseline kod N ili C krajeve od izvorne sekvence peptida, koji nisu sadržani u T stanici epitopa brišu se, i / ili vi) bilo koje dvije uzastopne aminokiseline koje sadrže sekvencu Asp-u Gly sve do četiri aminokiseline kod N ili C krajeva od izvorne sekvence peptida, koji nisu sadržani u T stanici epitopa brišu se.
The method for decorating the sides of plastic cards according to claim 1, wherein the plurality of cards comprises of 25 cards. 
Postupak ukrašavanja strana plastičnih karata u skladu s patentnim zahtjevom 1, naznačena time što se više karata sastoji od 25 karata.
co-processing a feedstock in the presence of a catalyst, the fuel comprising a product of a fluidized catalytic cracker co-processing a feedstock, said feedstock comprising: 
ko-procesiranje sirovine u prisutnosti katalizatora, gorivo sadrži proizvod fluidiziranog katalitičkog krekera koji ko-procesira sirovinu, navedena sirovina sadrži:
plasma coating the interior surface and/or epoxy-coating the exterior surface. 
premazivanje unutarnje površine s plazmom i/ili premazivanje vanjske površine s epoksidnom prevlakom.
The cells or article of manufacture for use according to for use according to any one of claims 5 and 7 to 10, wherein culturing conditions of said three-dimensional culture comprise an adherent material selected from the group consisting of a polyester and a polypropylene. 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 1 7 do 10, naznačeni time što uvjeti uzgoja u navedenoj trodimenzionalnoj kulturi uključuju adherentni materijal, koji se bira iz skupine koju čine poliester i polipropilen.
Changes in the fingernails of old people are mostly related to diminished tissue repair and inflammatory or degenerative changes of the distal interphalangeal joint. 
Promjene na noktima prstiju kod starijih osoba često su povezane sa smanjenom sposobnosti popravka tkiva te upalnim ili degenerativnim promjenama distalnog interfalangealnog zgloba.
A product containing the composition of claim 16 and a second pharmaceutical agent, as a combined preparation for simultaneous, separate or sequential use as a medicament. 
Proizvod koji sadrži sastav prema patentnom zahtjevu 16 i drugi farmaceutski agens kao kombinirani pripravak, naznačen time, da jest za simultanu, separatnu ili sekvencijalnu primjenu kao lijek.
A method according to claim 17 wherein the solvent is N-methylpyrrolidone. A method according to claim 1 wherein the temperature ranges from 20 to 200°C, preferably from 40 to 85°C. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je temperatura u opsegu od 20 do 200°C, poželjno od 40 do 85°C.
An isolated antisense oligonucleotide of up to 50 nucleotides in length, wherein the antisense oligonucleotide comprises the antisense oligonucleotide of claim 1. 
Izolirani antisens oligonukleotid dug do 50 nukleotida, naznačen time što navedeni antisens oligonukleotid sadrži antisens oligonukleotid u skladu sa zahtjevom 1.
represents Thr, R1 represents OH, or a salt or solvate thereof. 
predstavlja Thr, predstavlja OH, ili njegova sol ili solvat.
Low carbon steel strips of the dual phase type (ferrite-martensite) are known, being cold rolled, which have special geometrical, and metallurgical features, as well as relating to planarity and deformability, so as to render the same particularly adapted to the production of pressed or cut pieces requiring very strict tolerances, particularly when designed for the car manufacturing industry with a thickness of more than 1.0 mm. 
Čelične trake sa niskim sadržajem ugljika dvofaznog tipa (ferit-martenzit) su poznate, hladno su valjane, i imaju posebne geometrijske i metalurške karakteristike, kao i u svezi sa planarnošću i sposobnošću deformiranja, tako da su ove trake posebno prilagođene za proizvodnju prešanih ili izrezanih komada koji zahtjevaju vrlo mala odstupanja, posebno kada su konstruirane za automobilsku industriju sa debljinama od više od 1.0 mm.
The reaction mixture was cooled to ambient temperature. 
Reakcijsku smjesu ohladi se na temperaturu okoliša.
specifically binds to the motifs RNIQF and WVIH of human CD38 (SEQ ID No:31), or comprises human light chain and human heavy chain variable regions, wherein the light chain variable region comprises a VL CDR1 having the sequence as set forth in SEQ ID No:3, a VL CDR2 having the sequence as set forth in SEQ ID No:4 and a VL CDR3 having the sequence as set forth in SEQ ID No:5, and the heavy chain variable region comprises a VH CDR1 having the sequence as set forth in SEQ ID No:8, a VH CDR2 having the sequence as set forth in SEQ ID No:9 and a VH CDR3 having the sequence as set forth in SEQ ID No:10. 
Monoklonsko protutijelo koje se vezuje za humani CD38, pri čemu navedeno protutijelo sadrži humani laki lanac i varijabilne regije humanog teškog lanca, pri čemu varijabilna regija lakog lanca sadrži VL CDR1 koji ima slijed naveden u SEQ ID No: 13, VL CDR2 koji ima slijed naveden u SEQ ID br: 14 i VL CDR3 koji ima slijed naveden u SEQ ID br: 15, a varijabilno područje teškog lanca sadrži VH CDR1 koji ima slijed kao što je navedeno u SEQ ID br: 18, VH CDR2 koji ima slijed naveden u SEQ ID br:19 i VH CDR3 koji ima slijed kako je navedeno u SEQ ID br:20.
The combination of Claim 10, for use in treatment of a bacterial infection, wherein the bacterial infection is caused by an Acinetobacter spp. pathogen, a Burkholderia spp. pathogen, P. aeruginosa, or Enterobacteriaceae. 
Kombinacija sukladno patentnom zahtjevu 10, radi liječenja bakterijske infekcije, naznačena time da je bakterijska infekcija prouzročena patogenom Acinetobacter spp., patogenom Burkholđeria SPp., P. aeruginosa, ili Enterobacteriaceae.